1-3 of 3
Jay Hocking, MD PhDstudent
Close
Sort by
Journal Articles

High Risk Multiple Myeloma: Better Outcomes with Upfront Tandem Autologous- Non-Myelo Ablative Allogeneic Stem Cell Transplantation Compared to Upfront Autologous Stem Cell Transplantation

Anish Puliyayil Nair, MD DM, FRACP, Cindy Lee, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Krystal Bergin, Jay Hocking, MD PhDstudent, Sue Morgan, FRACP, FRCPA, MBBS, Daniela Klarica, RN, Jenny Muirhead, Andrew Spencer, Oi Lin Lee, Noemi Horvath, MB, ChB, FRACP, FRCPA
Journal: Blood
Blood (2016) 128 (22): 4684.
https://doi.org/10.1182/blood.V128.22.4684.4684
Published: 2016
Journal Articles

TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma

Antonia Reale, MD Oncologist in training, Tiffany Khong, BSc, PhD, Sridurga Mithraprabhu, PhD, John Reynolds, Malarmathy Ramachandran, Ioanna Savvidou, MD PhD, Krystal Bergin, Jay Hocking, MD PhDstudent, Andrew Spencer
Journal: Blood
Blood (2016) 128 (22): 4461.
https://doi.org/10.1182/blood.V128.22.4461.4461
Published: 2016
Journal Articles

Mutational Characterisation and Tracking Disease Progression Using Circulating Cell-Free Tumor DNA in Multiple Myeloma Patients

Sridurga Mithraprabhu, PhD, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Annie W.S. Chow, Daniela Klarica, RN, Laura Mai, Stephanie Walsh, David Broemeling, Andre Marziali, Matthew Wiggin, Jay Hocking, MD PhDstudent, Anna Kalff, MBBS, FRACP, FRCPA, Brian G.M. Durie, MD, Andrew Spencer
Journal: Blood
Blood (2016) 128 (22): 3280.
https://doi.org/10.1182/blood.V128.22.3280.3280
Published: 2016